MedTrace Logo

Electroconvulsive Therapy in Clozapine Refractory Schizophrenia

NCT00042224 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-05-15

Study results available
· View outcomes & findings →

Summary

This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine.

Conditions

Interventions

PROCEDURE

Electroconvulsive Therapy (ECT)

ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.

DRUG

Clozapine

Patients with psychotic symptoms will receive clozapine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Northwell Health

    lead OTHER

Principal Investigators

  • Georgios Petrides, MD · New Jersey Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-12-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00042224 on ClinicalTrials.gov